Is SELLAS Life Sciences Group, Inc. (SLS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 1.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 1.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 5.2% / 33% | 71.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 1.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 5.2% / 33% | 71.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -66.9% | |
| Return on Assets (ROA) | -34.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$35M |
| Free Cash Flow | -$35M |
| Total Debt | $1M |
| Debt-to-Equity | 1.4 |
| Current Ratio | 10.7 |
| Total Assets | $19M |
Price & Trading
| Last Close | $4.95 |
| 50-Day MA | $4.55 |
| 200-Day MA | $2.63 |
| Avg Volume | 9.3M |
| Beta | 2.2 |
|
52-Week Range
$0.95
| |
About SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SELLAS Life Sciences Group, Inc. (SLS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SELLAS Life Sciences Group, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SELLAS Life Sciences Group, Inc.'s debt ratio?
SELLAS Life Sciences Group, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.2%.
What are SELLAS Life Sciences Group, Inc.'s key financial metrics?
SELLAS Life Sciences Group, Inc. has a market capitalization of $784M. Return on equity stands at -66.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.